NYSE:VNRX VolitionRx (VNRX) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free VNRX Stock Alerts $0.77 -0.03 (-3.75%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.77▼$0.8050-Day Range$0.60▼$1.0652-Week Range$0.55▼$1.79Volume75,235 shsAverage Volume348,840 shsMarket Capitalization$63.77 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get VolitionRx alerts: Email Address VolitionRx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside224.7% Upside$2.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.66 out of 5 starsMedical Sector688th out of 920 stocksDiagnostic Substances Industry10th out of 13 stocks 3.5 Analyst's Opinion Consensus RatingVolitionRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVolitionRx has only been the subject of 1 research reports in the past 90 days.Read more about VolitionRx's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VNRX. Previous Next 0.0 Dividend Strength Dividend YieldVolitionRx does not currently pay a dividend.Dividend GrowthVolitionRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VNRX. Previous Next 3.7 News and Social Media Coverage News SentimentVolitionRx has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for VolitionRx this week, compared to 0 articles on an average week.Search Interest1 people have searched for VNRX on MarketBeat in the last 30 days. MarketBeat Follows2 people have added VolitionRx to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VolitionRx insiders have not sold or bought any company stock.Percentage Held by Insiders15.40% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.09% of the stock of VolitionRx is held by institutions.Read more about VolitionRx's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of VolitionRx is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VolitionRx is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About VolitionRx Stock (NYSE:VNRX)VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.Read More VNRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNRX Stock News HeadlinesMay 18 at 5:36 AM | americanbankingnews.comVolitionRx (NYSE:VNRX) Rating Reiterated by Cantor FitzgeraldMay 15, 2024 | finance.yahoo.comVolitionRX Ltd (VNRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances and ...May 13, 2024 | washingtonpost.comVolitionRX: Q1 Earnings SnapshotMay 13, 2024 | prnewswire.comVolitionRx Limited Announces First Quarter 2024 Financial Results and Business UpdateMay 12, 2024 | americanbankingnews.comStockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)May 8, 2024 | prnewswire.comVolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business UpdateApril 8, 2024 | msn.comVNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method ...April 8, 2024 | finance.yahoo.comVNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for SepsisMarch 25, 2024 | msn.comVNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023March 25, 2024 | prnewswire.comVolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business UpdateMarch 22, 2024 | benzinga.comEarnings Outlook For VolitionRXMarch 21, 2024 | prnewswire.comVolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business UpdateMarch 21, 2024 | finanznachrichten.deVolitionRx Limited: Volition appoints Dr Andrew Retter as Chief Medical OfficerMarch 19, 2024 | markets.businessinsider.comVolitionRx Names Andrew Retter Chief Medical OfficerMarch 19, 2024 | finance.yahoo.comVolition appoints Dr Andrew Retter as Chief Medical OfficerMarch 19, 2024 | money.usnews.comVolitionRX LtdFebruary 22, 2024 | benzinga.comVolitionRX Stock (AMEX:VNRX), Short Interest ReportJanuary 2, 2024 | msn.comVolitionRx stock soars after company discloses $13M in milestone paymentsJanuary 2, 2024 | realmoney.thestreet.comVolitionRx milestone payment 'important step forward,' says EF HuttonNovember 17, 2023 | finance.yahoo.comVolition Presents at the 5th Annual Congress of the International Liquid Biopsy SocietyNovember 8, 2023 | proactiveinvestors.comVolitionRx to host Q3 earnings call on November 15October 28, 2023 | markets.businessinsider.comVolitionRX’s Innovative Cancer Detection Platform: A Promising Investment – An Analyst’s PerspectiveSee More Headlines Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today5/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNYSE:VNRX CUSIPN/A CIK93314 WebN/A Phone646-650-1351Fax65 32 8172 5651Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$2.50 Low Stock Price Target$2.50 Potential Upside/Downside+224.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,320,000.00 Net Margins-4,379.67% Pretax Margin-4,426.10% Return on EquityN/A Return on Assets-150.15% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.69 Sales & Book Value Annual Sales$770,000.00 Price / Sales82.82 Cash FlowN/A Price / Cash FlowN/A Book Value($0.20) per share Price / Book-3.85Miscellaneous Outstanding Shares82,820,000Free Float70,069,000Market Cap$63.77 million OptionableOptionable Beta1.26 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Martin Charles Faulkes Ph.D. (Age 80)Executive Chairman Comp: $239.51kMr. Cameron Reynolds MBA (Age 53)Founder, CEO, President & Director Comp: $572.43kDr. Gaetan Michel Ph.D. (Age 50)Chief Operating Officer Comp: $518.15kDr. Salvatore Thomas Butera DVM (Age 72)Chief Executive Officer of Volition Veterinary Diagnostics Development LLC Comp: $477.25kMr. Terig Hughes (Age 53)CFO & Treasurer Comp: $338.74kDr. Jacob Vincent Micallef MBA (Age 68)Ph.D., Chief Scientific Officer Comp: $571.55kMr. Nicholas Plummer (Age 53)Group General Counsel Ms. Louise Batchelor Day (Age 52)Group Chief Marketing & Communications Officer Mr. Thomas BygottSales & Marketing DirectorMr. Gael Forterre M.B.A. (Age 42)Chief Commercial Officer More ExecutivesKey CompetitorsAlpha TeknovaNASDAQ:TKNOARCA biopharmaNASDAQ:ABIOImmuCellNASDAQ:ICCCAspira Women's HealthNASDAQ:AWHOncoCyteNASDAQ:OCXView All CompetitorsInsidersCorp Ltd EightSold 20,000 sharesTotal: $18,000.00 ($0.90/share)Salvatore Thomas ButeraBought 10,000 shares on 12/18/2023Total: $8,300.00 ($0.83/share)Corp Ltd EightSold 20,000 sharesTotal: $15,000.00 ($0.75/share)Salvatore Thomas ButeraBought 10,000 shares on 12/15/2023Total: $7,700.00 ($0.77/share)Rodney Gerard RootsaertBought 10,000 shares on 12/13/2023Total: $6,000.00 ($0.60/share)View All Insider Transactions VNRX Stock Analysis - Frequently Asked Questions Should I buy or sell VolitionRx stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VNRX shares. View VNRX analyst ratings or view top-rated stocks. What is VolitionRx's stock price target for 2024? 1 analysts have issued 1 year target prices for VolitionRx's stock. Their VNRX share price targets range from $2.50 to $2.50. On average, they predict the company's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 224.7% from the stock's current price. View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts. How have VNRX shares performed in 2024? VolitionRx's stock was trading at $0.7170 at the beginning of 2024. Since then, VNRX stock has increased by 7.4% and is now trading at $0.77. View the best growth stocks for 2024 here. How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSE:VNRX) posted its quarterly earnings data on Monday, May, 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:VNRX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.